A Double-blind, Randomised, Placebo-controlled, Crossover Study to Assess the Efficacy of XEN-D0501, a Transient Receptor Potential Vanilloid Receptor 1 (TRPV1) Antagonist, in Reducing the Frequency of Cough in Patients With Chronic Idiopathic Cough.

Trial Profile

A Double-blind, Randomised, Placebo-controlled, Crossover Study to Assess the Efficacy of XEN-D0501, a Transient Receptor Potential Vanilloid Receptor 1 (TRPV1) Antagonist, in Reducing the Frequency of Cough in Patients With Chronic Idiopathic Cough.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs XEN D0501 (Primary)
  • Indications Cough
  • Focus Therapeutic Use
  • Sponsors Xention
  • Most Recent Events

    • 24 May 2017 Primary endpoint (Change from baseline after 14-days treatment in objective daytime cough frequency on XEN-D0501 compared to placebo) has not been met, according to the results presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results assessing efficacy of XEN-D0501 in pre-clinical and clinical capsaicin cough challenge studies, presented at the 113th International Conference of the American Thoracic Society
    • 14 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top